Pancrelipase delayed release - Nestle
Alternative Names: APT-1008; Enzepi; EUR-1008; EUR-1008M; Zenpep; ZentaseLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Eurand
- Developer Allergan; Nestle
- Class Pancreatic enzymes
- Mechanism of Action Pancrelipase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pancreatic disorders
Most Recent Events
- 05 May 2020 Allergan has divested the drugs Zenpep and Viokace to Nestle
- 13 Mar 2018 Discontinued - Phase-III for Pancreatic disorders in Ukraine (PO) (NCT00788593)
- 29 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval of Pancrelipase for Pancreatic disorders (exocrine pancreatic insufficiency in patients with cystic fibrosis) in EU